Drugs / Dimethyltryptamine
Dimethyltryptamine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06772753 | Feb 2025 → Jun 2027 expected | — | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 1 | NCT04353024 | Jun 2021 → Aug 2022 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06524830 | Dec 2024 → Aug 2026 overdue | — | atai Therapeutics, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT06070649 Comparator | Aug 2025 → Aug 2027 expected | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT04711915 Comparator | Mar 2021 → Jul 2026 overdue | major depressive disorder | Yale University | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimethyltryptamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04711915 ↗ |
| Known as | DMT | “N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings.” NCT04353024 ↗3“the psychedelic dimethyltryptamine (DMT), in addition to a short course of psychotherapy, on Alcohol Use Disorder (AUD).” NCT06070649 ↗ “0.1 mg/kg Dimethyltryptamine (DMT)” NCT04711915 ↗ “Drug: Dimethyltryptamine (DMT)” NCT06772753 ↗ |
| Known as | N,N-dimethyltryptamine | “N,N-dimethyltryptamine (DMT) is a naturally-occurring psychedelic substance widely used in recreational and spiritual settings.” NCT04353024 ↗ |
| Known as | VLS-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06524830 ↗ |
| Route | Intravenous | “Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min” NCT04353024 ↗ |